CAS NO: | 380623-76-7 |
包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 328.7 |
Cas No. | 380623-76-7 |
Formula | C10H5ClN4O5S |
Synonyms | SM-7368 |
Solubility | ≤100mg/ml in DMSO |
Chemical Name | 3-chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide |
Canonical SMILES | ClC1=C([N+]([O-])=O)C=CC(C(NC2=NC=C([N+]([O-])=O)S2)=O)=C1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
NF-κB Activation Inhibitor III is a NF-κB inhibitor.
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex controling transcription of DNA, cytokine production as well as cell survival. NF-κB is found in nearly all animal cell types and is involved in cellular responses to stimuli such as cytokines, stress, free radicals, heavy metals, and bacterial or viral antigens.
In vitro: Previous study found that NF-κB Activation Inhibitor III could inhibite TNF-a-induced MMP-9 upregulation in concentration-dependently and showed maximal activity at 10 μM. NF-κB Activation Inhibitor III also inhibited TNF-a-induced MMP-9 mRNA transcript accumulation and protein expression. It was also found that NF-κB Activation Inhibitor III strongly inhibited TNF-a-induced NF-jB activity but not AP-1 activity. In addition, NF-κB Activation Inhibitor III was able to strongly inhibit the TNF-a-induced invasion of HT1080 human fibrosarcoma cell line. These findings demonstrated that NF-κB Activation Inhibitor III was a synthetic compound inhibiting TNF-a-induced MMP-9 expression, and therefore NF-κB Activation Inhibitor III would be useful for the development of chemotherapy targeting TNF-a-mediated tumor invasion and metastasis [1]. NF-κB Activation Inhibitor III was used to disrupt NF-κB signaling to evaluate the role of syndecans in mediating extracellular matrix integrity [2].
In vivo: So far, there is no animal in vivo data reported.
Clinical trial: Up to now, NF-κB Activation Inhibitor III is still in the preclinical development stage.
References:
[1] H. Y. Lee, K. S. Park, M. K. Kim, et al. A small compound that inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 upregulation. Biochemical and Biophysical Research Communications 336(2), 716-722 (2005).
[2] H. Yang, H. Liu, X. Li, et al. TNF-α and TGF-β1 regulate Syndecan-4 expression in nucleus pulposus cells: Role of the mitogen-activated protein kinase and NF-κB pathways. Connect.Tissue Res. 56(4), 281-287 (2015).